Identification of cell types and metabolic pathways contributing to immune modulation by the flagellin:allergen fusion protein rFlaA:Betv1 and a MPLA adjuvanted therapy allergen preparation
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: To overcome the current limitations concerning safety, efficiency, and convenience in allergen-specific immunotherapy (AIT), new treatment strategies are required. Here, novel adjuvants and molecular approaches are potentially effective strategies. This thesis investigated two novel adjuvant-based approaches to modulate allergic immune responses: the therapy allergen product Pollinex® Quattro (PQ) and the experimental fusion protein rFlaA:Betv1. Currently, the first-generation adjuvant L-tyrosine and the “Toll” like receptor (TLR) 4-ligand and second-generation adjuvant monophosphoryl lipid A (MPLA) are combined with polymerized allergen molecules (allergoids) in a therapeutic allergen product called PQ which was hypothesized to improve tree pollen AIT. However, the mechanisms contributing to the activation of immune cells by this AIT product are not fully elucidated. Besides classical mixtures of adjuvant(s) and allergen (such as PQ), the covalent fusion of allergen and adjuvant as part of novel allergen therapeutics was shown to prevent allergic sensitization. The fusion protein rFlaA:Betv1, combining both the TLR5- and nucleotide-binding leucine-rich repeat (NLR) family caspase recruitment domain (CARD) domain containing 4 (NLRC4)-ligand flagellin A (rFlaA) and the major birch pollen allergen Bet v 1, is an example of a novel type of therapy allergen product, in which allergen and adjuvant are combined into a single molecule. In the past, the conjugate rFlaA:Betv1 was shown to activate myeloid dendritic cells (mDCs) in vitro, while significantly suppressing sensitization towards Bet v 1 in vivo in a mouse model. Aim: Within the here summarized studies, we investigated the immune-modulating properties of PQ in mDCs. Furthermore, the metabolic pathways contributing to the effector functions of mDCs stimulated with either the fusion protein rFlaA:Betv1 or PQ were determined. Since the interplay of various immune cells is crucial in the context of AIT, the rFlaA:Betv1-induced activation of epithelial cells, macrophages, and B cells was tested for their ability to contribute to the in vivo investigated TH2-suppressing immune modulatory properties of rFlaA:Betv1. Methods: Murine bone marrow-derived mDCs were stimulated with either different AIT products, TLR-ligands, PQ, rFlaA:Betv1, or the equimolar amounts of the respective controls. Furthermore, mDCs were pre-treated with a variety of inhibitors to investigate the contribution of specific metabolic pathways (glycolysis, fatty acid- and amino acid metabolism, mitochondrial respiration) upon either rFlaA:Betv1- or PQ-mediated mDC activation. Besides mDCs, the rFlaA:Betv1-mediated activation of macrophages differentiated from the bone marrow of naïve mice was investigated, while the LA-4 cell line as used to elucidate the activation of epithelial cells by rFlaA:Betv1. Furthermore, B cells were either isolated from human buffy coats or purified from spleens of naïve C57BL/6, TLR5-/-, or MyD88-/- mice. rFlaA:Betv1-stimulated B cells were analyzed for the induced expression of regulatory B cell surface markers, cytokine secretion, and IgG- and IgA-antibody production. The ability to suppress Bet v 1-specific TH2 responses in a co-culture model with TH2-biased Bet v 1-specific CD4+ T cells was tested after either stimulation with PQ or rFlaA:Betv1 in mDCs. Additionally, the TH2-suppressing capacity of rFlaA:Betv1-stimulated macrophages and B cells was tested. The metabolic state of either rFlaA:Betv1- or PQ-stimulated immune cells was determined by extracellular flux assays and correlated to immune cell activation determined by cytokine and antibody production measured by ELISA as well as surface marker expression analyzed by flow cytometry. Results: Nearly all TLR-Ligands, the MPLA-containing PQ, and rFlaA:Betv1, but not aluminum hydroxide-adjuvanted AIT products, triggered Warburg metabolism and cytokine secretion in mDCs. Metabolic short-term analysis of mDCs showed that PQ increased both the extracellular acidification rate (ECAR) and the oxygen consumption rate (OCR). In contrast, rFlaA:Betv1 shifted the metabolism of mDCs and macrophages towards increased ECAR, while their OCR was reduced. Interestingly, the metabolic shift of rFlaA:Betv1-stimulated mDCs towards Warburg metabolism, likely associated with a disrupted Krebs cycle, presumably led to the generation of soluble anti-microbial effector molecules, as supernatants from rFlaA:Betv1-stimulated mDCs inhibited E. coli growth in a fatty acid- and glucose metabolism-dependent manner. In a co-culture with TH2-biased, Bet v 1-specific CD4+ T cells, the previously investigated TH2-suppressive, TH1-inducing, and IL-10-producing capacity of rFlaA:Betv1-stimulated mDCs was demonstrated to rely mainly on fatty acid synthesis. Besides rFlaA:Betv1-stimulated mDCs, rFlaA:Betv1-stimulated macrophages demonstrated the secretion of TH1 cytokines which are related to an M1 macrophage phenotype. Moreover, rFlaA:Betv1-stimulated macrophages were shown to dose-dependently reduce Bet v 1-induced TH2-response in a co-culture with TH2-biased Bet v 1-specific CD4+ T cells. In contrast, stimulation of mDCs with PQ was insufficient to suppress TH2 responses within the mDC:TC co-culture model. Furthermore, rFlaA:Betv1-stimulated B cells displayed an mTOR-independent but MyD88-dependent induction of a regulatory phenotype (CD19+CD1d+CD24+CD38+IgM+IL 10+) characterized by IL 10 secretion and the production of antigen-binding IgG, and non-antigen binding IgA antibodies. These B cells displayed a suppressive capacity in a triple co-culture with TH2-biased, Bet v 1-specific CD4+ T cells and mDCs. Discussion: Short-term activation of rFlaA:Betv1-stimulated mDC and macrophages resulted in a metabolic shift characterized by reduced oxidative phosphorylation paralleled by increased rates of glycolysis. Here, the accumulation of intermediates from the disrupted Krebs cycle was suggested to result in the generation of anti-microbial molecules. In contrast, mDC-stimulation with PQ increased both glycolysis and oxygen consumption. The results suggest, that the increased oxygen consumption could be driving an oxidative burst, leading to the generation of reactive oxygen species, as a further short-term defense mechanism. Therefore, the accumulation of metabolic intermediates, induced by both rFlaA:Betv1- and PQ-stimulation, likely contributes to immune cell effector function. Moreover, rFlaA:Betv1 acted as a thymus-independent B cell antigen, leading to the differentiation of IL-10-producing, regulatory B cells (Bregs) in an mTOR- and MyD88-dependent pathway. Mechanistically, the rFlaA:Betv1-mediated shift towards TH1-promoting phenotypes in all professional antigen-presenting cells investigated (mDCs, macrophages, and B cells), as well as the induction of Bregs, the production of allergen-neutralizing IgG antibodies and the subsequent clearance of allergen-antibody complexes by phagocytosing macrophages, accompanied by the suppression of allergen-induced TH2 responses, may promote rFlaA:Betv1-mediated immune modulation in AIT. Outlook: Since drugs for various diseases such as diabetes, transplantation, and cancer (may) interact with the patient's metabolism, it is important to understand the relationship between immune (cell) metabolism and effector function. The here discussed studies on novel therapeutic allergen products provide new insights into the relationship between the effector function of different immune cells and their underlying immune metabolism. These findings contribute to a deeper understanding of how immune metabolism is regulated by vaccination, allergen-specific immunotherapy, cancer treatment, and other physiological processes.
Fields of Study & Subjects
Allergic Rhinitis and Sensitization
Food Allergy and Anaphylaxis Research
Immunotherapy and Immune Responses
Publication details
- Journal / source
- TUbilio (Technical University of Darmstadt)
- Publication date
- 14 March 2026
- Language
- EN
- Document type
- Thesis